A. Bruce Montgomery, MD; David W. Feigal, MD; John M. Luce, MD; Philip C. Hopewell, MD; Daniel F. Hoth, MD; Maureen W. Myers, PhD; Judith E. Feinberg, MD; John Mills, MD; Fred R. Sattler, MD
To the Editor: In a recent editorial Armstrong and Bernard (1) stated that "aerosol pentamidine should not be used for treatment of Pneumocystis carinii pneumonia" because of excess risk of treatment failure, disseminated pneumocystosis, pulmonary hemorrhage, and death with this form of therapy. These conclusions are not supported by data available to the authors at the time the editorial was written. The work of Godfrey-Faussett, Miller and Semple (Nebulized pentamidine [Letter]. Lancet. 1988;1:645-6) cited by Armstrong and Bernard to support their editorial has been repeated with a different aerosol delivery system (2). With the Respirgard II jet nebulizer being used
Montgomery AB, Feigal DW, Luce JM, Hopewell PC, Hoth DF, Myers MW, et al. Aerosolized Pentamidine and Pneumocystis carinii Pneumonia. Ann Intern Med. ;110:669. doi: 10.7326/0003-4819-110-8-669_1
Download citation file:
Published: Ann Intern Med. 1989;110(8):669.
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use